comprehensive -WSS

comprehensive

author：leisure time 2025-09-03 14:37:13 - browse：359

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Astellas still sees hope in its gene therapy after four deaths

WSS

Wegovy, Zepbound and weight loss drugs that preserve muscle

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

comprehensive

hotspot

Apple is now the first public company to be valued at $3 trillion

FDA's Woodcock to retire early next year

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Jerome Adams on the need for new antivirals for Covid

Childhood cancer progress stalls for Black, Hispanic kids: Report

Virginia high school admissions case could be legal follow

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Dobbs anniversary: the lost opportunity of abortion as health care

Opioid cravings were reduced by anti

entertainment

Hospitals are piloting generative AI tools as regulators play catch

David Sabatini, ex

Surprise medical billing ban raises prices elsewhere

MD Anderson's Padmanee Sharma responds to research credit suit

Measles policy set amid Florida outbreak alarms vaccine proponents

New study raises questions about niacin and heart health

focus

Wikipedia

hotspot

Wikipedia